We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-22.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$402M
AUM Growth
-$164M
Cap. Flow
+$47.9M
Cap. Flow %
11.9%
Top 10 Hldgs %
62.89%
Holding
86
New
14
Increased
17
Reduced
23
Closed
25
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$55.3M
2
AMRN icon
Amarin Corp
AMRN
+$43M
3
TGTX icon
TG Therapeutics
TGTX
+$21.3M
4
APLS icon
Apellis Pharmaceuticals
APLS
+$20.9M
5
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$15.8M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$21.9M
2
BOLD icon
Audentes Therapeutics, Inc
BOLD
+$18.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$16M
4
ENSG icon
The Ensign Group
ENSG
+$14M
5
SNY icon
Sanofi
SNY
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.24%
2 Miscellaneous 5.59%
3 Communication Services 2.07%
4 Financials 0.11%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BHVN icon
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.62M 0.9%
+106,385
New +$4.86M
2020 Q1
0 quarters
IOVA icon
27
Iovance Biotherapeutics
IOVA
$6.26B
$2.7M 0.67%
+90,047
New +$2.39M
2020 Q1
0 quarters
GNMK
28
DELISTED
GenMark Diagnostics, Inc
GNMK
$2.16M 0.54%
+524,257
New +$2.46M
2020 Q1
0 quarters
CYTK icon
29
Cytokinetics
CYTK
$8.65B
$2.14M 0.53%
181,700
– –
2019 Q3
2 quarters
CYH icon
30
Community Health Systems
CYH
$409M
$1.94M 0.48%
580,350
-14
-0% -$57
2019 Q3
2 quarters
ALGN icon
31
PUT
Align Technology
ALGN
$10.4B
$1.74M 0.43%
+10,000
New +$2.39M
2020 Q1
0 quarters
NVST icon
32
Envista
NVST
$3.69B
$1.63M 0.41%
109,212
-397,466
-78% -$10.2M
2019 Q3
2 quarters
OXFD
33
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.59M 0.4%
172,193
-177,630
-51% -$2.48M
2019 Q3
2 quarters
AGRX
34
DELISTED
Agile Therapeutics
AGRX
$1.32M 0.33%
356
-212
-37% -$1.22M
2019 Q3
2 quarters
MYOK
35
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.3M 0.32%
27,752
+6,300
+29% +$404K
2019 Q4
1 quarter
ALBO
36
DELISTED
Albireo Pharma Inc
ALBO
$1.28M 0.32%
78,029
– –
2018 Q1
8 quarters
AUTL icon
37
Autolus Therapeutics
AUTL
$429M
$1.26M 0.31%
+210,013
New +$1.94M
2020 Q1
0 quarters
IMVT icon
38
Immunovant
IMVT
$5.48B
$1.2M 0.3%
76,866
– –
2019 Q4
1 quarter
LQDA icon
39
Liquidia Corp
LQDA
$3.02B
$1.15M 0.29%
244,637
-39,466
-14% -$196K
2019 Q4
1 quarter
HSKA
40
DELISTED
Heska Corp
HSKA
$1.15M 0.29%
20,771
– –
2019 Q1
4 quarters
OTIC
41
DELISTED
Otonomy, Inc.
OTIC
$1.11M 0.28%
561,737
+11,072
+2% +$34.1K
2019 Q1
4 quarters
DRNA
42
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.1M 0.27%
59,774
+41,100
+220% +$799K
2018 Q2
7 quarters
TLGT
43
DELISTED
Teligent, Inc
TLGT
$1.08M 0.27%
386,290
-63,890
-14% -$259K
2017 Q4
9 quarters
SCPH icon
44
DELISTED
scPharmaceuticals
SCPH
$980K 0.24%
132,419
-169,217
-56% -$1.23M
2019 Q2
3 quarters
KRSA
45
Korsana Biosciences, Inc. Common Stock
KRSA
$1.48B
$893K 0.22%
+2,408
New +$1.2M
2020 Q1
0 quarters
AFMD icon
46
DELISTED
Affimed
AFMD
$886K 0.22%
56,080
-29,697
-35% -$707K
2018 Q1
8 quarters
XENE icon
47
Xenon Pharmaceuticals
XENE
$3.25B
$812K 0.2%
71,591
-144,018
-67% -$2.05M
2018 Q3
6 quarters
TARA icon
48
Protara Therapeutics
TARA
$144M
$747K 0.19%
+32,478
New +$946K
2020 Q1
0 quarters
IFRX icon
49
InflaRx
IFRX
$197M
$747K 0.19%
195,488
-139,130
-42% -$515K
2019 Q4
1 quarter
CARM icon
50
DELISTED
Carisma Therapeutics
CARM
$729K 0.18%
65,000
– –
2019 Q4
1 quarter
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Eversept Partners held 86 positions worth $402M, down 29% from $566M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $47.9M of net new capital in Q1 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was HCA Healthcare: 101,000 shares worth $9.07M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was GSK, an estimated $21.9M trimmed.

  • Eversept Partners's largest Q1 2020 buy was HCA Healthcare: 101,000 shares worth $9.07M.
  • Eversept Partners added most to Zogenix, Inc. in Q1 2020, an estimated $55.3M increase.
  • Eversept Partners's biggest Q1 2020 reduction was GSK, cutting an estimated $21.9M.
  • Eversept Partners fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $18.3M.
  • Eversept Partners's ten largest holdings make up 63% of its $402M portfolio in Q1 2020.
  • Eversept Partners opened 14 new positions and closed 25 in Q1 2020.
  • Eversept Partners's portfolio value fell 29% quarter-over-quarter to $402M.

Based on Eversept Partners's 13F filing for Q1 2020, filed 13 May 2020.